摘要
目的探讨2017—2019年天津市眼科医院抗干眼症相关用药的使用情况和发展趋势。方法对2017—2019年天津市眼科医院抗干眼症相关药品的用药金额、用药频度(DDDs)、限定日费用(DDC)和药品排序比(B/A)进行统计分析。结果人工泪液类滴眼液用药金额占到抗干眼症相关用药总金额的60%以上,聚乙烯醇滴眼液用药金额稳居第1位。重组人表皮生长因子衍生物滴眼液DDDs排序上升排位最多,复合增长率最高。2017—2019年除了羧甲基纤维素钠滴眼液的DDC值略有上升外,其他滴眼液的DDC值均呈平稳及下降趋势。0.1%玻璃酸钠滴眼液(国产)的B/A值最高,53.3%的滴眼剂B/A接近1.00。结论天津市眼科医院抗干眼症相关药品的使用基本合理,人工泪液类滴眼液仍是抗干眼症的首选用药。
Objective To investigate the use and development trend of anti-xerophthalmia drugs in Tianjin Eye Hospital from 2017 to 2019.Methods The amount,DDDs,DDC and B/A of anti-xerophthalmia drugs in Tianjin Eye Hospital from 2017 to 2019 were statistically analyzed.Results The amount of artificial tear eye drops accounted for more than 60%of the total amount of antixerophthalmia drug,and the amount of polyvinyl alcohol eye drops was the first.DDDs sequence of recombinant human epidermal growth factor derivative eye drops increased the most and the compound growth rate was the highest.From 2017 to 2019,except sodium carboxymethyl cellulose eye drops DDC value slightly increased,other eye drops DDC value were flat and decreased.The B/A value of 0.1%sodium hyaluronate eye drops(made in China)was the highest,and 53.3%of the eye drops were close to 1.00.Conclusion The use of anti-xerophthalmia drugs in Tianjin Eye Hospital is reasonable and artificial tear drops are still the first choice for anti-xerophthalmia.
作者
陆海
马一平
LU Hai;MA Yi-ping(Tianjin Eye Hospital,Tianjin 300121,China)
出处
《现代药物与临床》
CAS
2021年第4期833-837,共5页
Drugs & Clinic
关键词
干眼症
人工泪液类滴眼液
聚乙烯醇滴眼液
重组人表皮生长因子衍生物滴眼液
xerophthalmia
artificial tear eye drops
polyvinyl alcohol eye drops
recombinant human epidermal growth factor derivative eye drops
